ABSTRACT
Introduction: There is an urgent medical need to differentiate active tuberculosis (ATB) from latent tuberculosis infection (LTBI) and prevent undertreatment and overtreatment. The aim of this study was to identify biomarker profiles that may support the differentiation between ATB and LTBI and to validate these signatures. Materials and Methods: The discovery cohort included adult individuals classified in four groups: ATB (n = 20), LTBI without prophylaxis (untreated LTBI; n = 20), LTBI after completion of prophylaxis (treated LTBI; n = 20), and healthy controls (HC; n = 20). Their sera were analyzed for 40 cytokines/chemokines and activity of adenosine deaminase (ADA) isozymes. A prediction model was designed to differentiate ATB from untreated LTBI using sparse partial least squares (sPLS) and logistic regression analyses. Serum samples of two independent cohorts (national and international) were used for validation. Results: sPLS regression analyses identified C-C motif chemokine ligand 1 (CCL1), C-reactive protein (CRP), C-X-C motif chemokine ligand 10 (CXCL10), and vascular endothelial growth factor (VEGF) as the most discriminating biomarkers. These markers and ADA(2) activity were significantly increased in ATB compared to untreated LTBI (p ≤ 0.007). Combining CCL1, CXCL10, VEGF, and ADA2 activity yielded a sensitivity and specificity of 95% and 90%, respectively, in differentiating ATB from untreated LTBI. These findings were confirmed in the validation cohort including remotely acquired untreated LTBI participants. Conclusion: The biomarker signature of CCL1, CXCL10, VEGF, and ADA2 activity provides a promising tool for differentiating patients with ATB from non-treated LTBI individuals.
Subject(s)
Adenosine Deaminase/blood , Chemokine CCL1/blood , Chemokine CXCL10/blood , Latent Tuberculosis/blood , Vascular Endothelial Growth Factor A/blood , Adult , Biomarkers/blood , Case-Control Studies , Cohort Studies , Cross-Sectional Studies , Female , Humans , Immunologic Tests , Latent Tuberculosis/diagnosis , Latent Tuberculosis/immunology , Logistic Models , Male , Middle Aged , Overtreatment/prevention & control , Sensitivity and Specificity , Young AdultABSTRACT
BACKGROUND: Falls are common among elderly adults, and are predictors of hospitalization, institutionalization and mortality. OBJECTIVE: The objective of the present study was to examine the relationship between blood-based markers of inflammation and fall events in a sample of elderly Hispanic adults. METHOD: Data were collected from 190 participants enrolled in the Panama Aging Research Initiative study who completed baseline clinical and cognitive assessments. A non-fasting blood sample was obtained. Self-reported falls were classified as no falls, single falls or recurrent (two or more) falls reported in the 12 months prior to baseline evaluations. Serum levels of C Reactive Protein (CRP), T-lymphocyte secreting protein (I-309), interleukin 10 (IL-10), interleukin 6 (IL-6) and interleukin 7 (IL-7) were measured. Global cognition was assessed with the Mini Mental State Examination and depressive symptoms were assessed with the Geriatric Depression Scale (GDS-30). Multinomial logistic regression was used to assess the link between inflammation and fall events. RESULTS: Depressive symptoms, limitations in Instrumental Activities of Daily Living (IADL), IL-7 and I-309 were significantly related to fall events. Elevated levels of IL-7 increased the likelihood of single and recurrent falls, while increased levels of I-309 were associated only with recurrent falls. Greater IADL limitations and depressive symptoms were associated with an increased likelihood of recurrent falls. CONCLUSION: There is a lack of research investigating the relationship between inflammatory biomarkers and fall events. These results provide evidence of risk factors for falls in Hispanic older adults, and could serve to guide public health professionals to establish clinical guidelines to reduce fall risks.
Subject(s)
Accidental Falls , Aging/blood , Aging/psychology , Depression/blood , Inflammation Mediators/blood , Accidental Falls/prevention & control , Accidental Falls/statistics & numerical data , Aged , Aged, 80 and over , Biomarkers/blood , C-Reactive Protein/metabolism , Chemokine CCL1/blood , Depression/complications , Female , Hispanic or Latino , Humans , Incidence , Interleukin-10/blood , Interleukin-6/blood , Interleukin-7/blood , Male , Panama/epidemiology , Risk FactorsABSTRACT
OBJECTIVE AND DESIGN: Angiogenic factors are proteins that are related to certain foetal chromosomal abnormalities. The aim of this study was to determine the concentration of 60 angiogenic factors in the plasma of women with offspring possessing trisomy 21/Down syndrome (DS). METHOD: After analysing karyotyping results, we selected 20 patients with foetuses possessing DS, and for the control group, we selected 28 healthy patients with uncomplicated pregnancies who delivered healthy newborns at term (i.e., 15-18 weeks of gestation). To assess the concentration of proteins in the blood plasma, we used a protein macroarray which enabled simultaneous determination of 60 angiogenic factors per sample. RESULTS: We observed a statistically significant increase in the concentration of these five angiogenic and inflammatory factors: TGFb1 (p = 0.039), angiostatin (p = 0.0142), I-309 (p = 0.0476), TGFb3 (p = 0.0395), and VEGF-D (p = 0.0173)-compared to concentrations in patients with healthy foetuses. CONCLUSION: Our findings suggest that angiogenic factors may play role in DS pathogenesis.
Subject(s)
Angiogenesis Inducing Agents/blood , Blood Proteins/genetics , Down Syndrome/blood , Maternal Inheritance/genetics , Angiostatins/blood , Chemokine CCL1/blood , Chromosome Aberrations , Down Syndrome/genetics , Down Syndrome/pathology , Female , Humans , Infant, Newborn , Karyotyping , Pregnancy , Transforming Growth Factor beta1/blood , Transforming Growth Factor beta3/blood , Vascular Endothelial Growth Factor D/bloodABSTRACT
Many patients with cutaneous T-cell lymphoma (CTCL) experience severe pruritus. This study evaluated serum levels of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in patients with CTCL. Although serum NGF and BDNF levels in patients with CTCL were not significantly higher than in healthy controls, serum NGF levels in patients with Sézary syndrome were higher than in those with mycosis fungoides and in healthy controls. Enhanced NGF expression by keratinocytes and increased dermal nerve fibres were detected in lesional skin of subjects with Sézary syndrome. Correlations between pruritus in CTCL and serum levels of NGF, BDNF, chemokine (C-C motif) ligand 1 (CCL1), CCL17, CCL26, CCL27, lactate dehydrogenase (LDH), IgE, and soluble interleukin-2 receptor were analysed. Serum CCL1, CCL26, LDH, and IgE levels correlated with pruritus in patients with CTCL. NGF may be associated with increased dermal nerve fibres and pruritus in Sézary syndrome, and CCL1, CCL26, and IgE may be associated with pruritus in CTCL.
Subject(s)
Biomarkers, Tumor/blood , Chemokine CCL1/blood , Chemokines, CC/blood , Immunoglobulin E/blood , Lymphoma, T-Cell, Cutaneous/immunology , Nerve Growth Factor/blood , Pruritus/immunology , Skin Neoplasms/immunology , Skin/innervation , Aged , Brain-Derived Neurotrophic Factor/blood , Case-Control Studies , Chemokine CCL26 , Female , Humans , Lymphoma, T-Cell, Cutaneous/blood , Lymphoma, T-Cell, Cutaneous/complications , Lymphoma, T-Cell, Cutaneous/pathology , Male , Middle Aged , Mycosis Fungoides/blood , Mycosis Fungoides/immunology , Pruritus/pathology , Sezary Syndrome/blood , Sezary Syndrome/immunology , Skin/pathology , Skin Neoplasms/blood , Skin Neoplasms/complications , Skin Neoplasms/pathologyABSTRACT
BACKGROUND: The recent recommendation of the U.S. Preventive Services Task Force against PSA-based screening for prostate cancer was based, in part, on the lack of demonstrated diagnostic utility of serum PSA values in the low, but detectable range to successfully predict prostate cancer. Though controversial, this recommendation reinforced the critical need to develop, validate, and determine the utility of other serum and/or urine transcript and protein markers as diagnostic markers for PCa. The studies described here were intended to determine whether inflammatory cytokines might augment serum PSA as a diagnostic marker for prostate cancer. METHODS: Multiplex ELISA assays were performed to quantify CCL1, CCL2, CCL5, CCL8, CCL11, CCL17, CXCL1, CXCL5, CXCL8, CXCL10, CXCL12, and IL-6 protein levels in the serum of 272 men demonstrating serum PSA values of <10 ng/ml and undergoing a 12 core diagnostic needle biopsy for detection of prostate cancer. Logistic regression was used to identify the associations between specific chemokines and prostate cancer status adjusted for prostate volume, and baseline PSA. RESULTS: Serum levels for CCL1 (I-309) were significantly elevated among all men with enlarged prostates (P < 0.04). Serum levels for CCL11 (Eotaxin-1) were significantly elevated among men with prostate cancer regardless of prostate size (P < 0.01). The remaining 10 cytokines examined in this study did not exhibit significant correlations with either prostate volume or cancer status. CONCLUSIONS: Serum CCL11 values may provide a useful diagnostic tool to help distinguish between prostatic enlargement and prostate cancer among men demonstrating low, but detectable, serum PSA values.
Subject(s)
Biomarkers, Tumor/blood , Chemokine CCL11/blood , Prostatic Neoplasms/blood , Prostatic Neoplasms/diagnosis , Aged , Biomarkers/blood , Biopsy , Chemokine CCL1/blood , Diagnosis, Differential , Humans , Kallikreins/blood , Male , Middle Aged , Neoplasm Grading , Predictive Value of Tests , Prostate/pathology , Prostate-Specific Antigen/blood , Prostatic Neoplasms/epidemiology , Risk FactorsSubject(s)
Blister/metabolism , Chemokine CCL1/blood , Pemphigoid, Bullous/blood , Adult , Aged , Aged, 80 and over , Chemokine CCL1/metabolism , Endothelial Cells/metabolism , Endothelial Cells/pathology , Female , Humans , Immunoglobulin E/blood , Male , Middle Aged , Pemphigoid, Bullous/metabolism , Pemphigoid, Bullous/pathologyABSTRACT
BACKGROUND: T-helper (Th) 2 cytokines are thought to mediate most of the allergic inflammatory responses associated with atopic asthma. But the Th1-related chemokine, interferon-inducible protein 10 (IP-10)/CXCL10, was the predominant chemokine measured during human allergic pulmonary late-phase reaction. The aim of the present study was to evaluate the role of Th1- and Th2- related chemokines in the pathogenesis of asthma exacerbation. METHODS: Plasma levels of the Th2-related C-C chemokine I-309 (CCL1), the Th1-related CXC chemokines IP-10, and the monokine induced by interferon-gamma (Mig)/CXCL9 were measured in patients with stable asthma. RESULTS: These results were compared to the results measured prior to, and after corticosteroid treatment, in patients who experienced asthma exacerbations. A significant increase in the plasma levels of IP-10 and Mig, but not I-309, were found in patients with an acute exacerbation in contrast to patients with stable asthma. Plasma levels of IP-10 and Mig were significantly higher in patients during an acute asthma exacerbation than during a subsequent convalescent period. CONCLUSIONS: The Th1-related CXC chemokines IP-10 and Mig may be useful inflammatory markers of asthma exacerbation in children.